Madrigal Pharmaceuticals (MDGL) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 304.8% versus a gain of 10.1%. Over five years, MDGL leads with a +447.5% price change compared with -58.1% for SYRE. Madrigal Pharmaceuticals is the larger company by market cap ($10.90 billion vs $7.91 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDGL | SYRE |
|---|---|---|
| Share price | $471.75 | $85.69 |
| Market cap | $10.90B | $7.91B |
| 1-day change | -1.08% | +7.25% |
| YTD return | -18.99% | +161.57% |
| 1-year return | +10.14% | +304.77% |
| 5-year return | +447.46% | -58.10% |
| Forward P/E | 49.01 | — |
| EPS (TTM) | $-12.85 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $958.40M | $0 |
| Revenue growth (YoY) | +432.05% | — |
| Net income (latest FY) | $-288.28M | $-155.20M |
| Operating margin | -31.31% | — |
| Net margin | -30.08% | — |
| 52-week high | $615.00 | $110.18 |
| 52-week low | $393.61 | $18.12 |
| Distance from 52-week high | -23.29% | -22.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +44.59% | +40.28% |
| Average volume | 289.24K | 1.22M |
| Shares outstanding | 23.10M | 92.29M |
| Employees | 915 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed MDGL by 294.6 percentage points over the past year.
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
MDGL vs SYRE FAQ
Which is bigger, Madrigal Pharmaceuticals or Spyre Therapeutics?
Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $10.90B compared with $7.91B for Spyre Therapeutics (SYRE).
Which stock has performed better over the past year, MDGL or SYRE?
SYRE returned +304.77% over the past 12 months, compared with +10.14% for MDGL (price return, excluding dividends). Past performance does not predict future results.
Are Madrigal Pharmaceuticals and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.